Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes - Darren K. McGuire; Nikolaus Marx; Sharon L. Mulvagh; John E. Deanfield; Silvio E. Inzucchi; Rodica Pop-Busui; Johannes F.E. Mann; Scott S. Emerson; Neil R. Poulter; Mads D.M. Engelmann; Maria Sejersten Ripa; G. Kees Hovingh; et al. (New England Journal of Medicine, 2025)